Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases.

ABSTRACT:

Objective

Rituximab remains the standard-of-care anti-CD20 therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a next-generation, glycoengineered anti-CD20 monoclonal antibody with enhanced B-cell-depleting capacity, may offer superior efficacy. We evaluated the efficacy and safety of reduced-dose obinutuzumab in 16 patients with active, refractory AAV at a single center in China.

Methods

In this retrospective chart review, we evaluated 16 consecutive patients who received reduced-dose obinutuzumab (most commonly 1,000 mg for induction) after failure to achieve remission with cyclophosphamide (CTX) and/or rituximab (RTX) or who presented with severe, treatment-naïve disease. Primary endpoints were complete remission (CR) rates a

SUBMITTER: Wu W 

PROVIDER: S-EPMC12426241 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature